We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+45.08%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$930M
AUM Growth
+$84.2M
Cap. Flow
-$119M
Cap. Flow %
-12.76%
Top 10 Hldgs %
65.22%
Holding
58
New
12
Increased
4
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
RGLS
Regulus Therapeutics
RGLS
+$70.3M
2
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22M
3
CHRS icon
Coherus Oncology
CHRS
+$21.9M
4
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$20M
5
TGTX icon
TG Therapeutics
TGTX
+$16.7M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$64.2M
2
DYAX
DYAX CORPORATION
DYAX
+$35.8M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$34.8M
4
DVAX
Dynavax Technologies
DVAX
+$17.4M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 64.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
51
Puma Biotechnology
PBYI
$398M
$587K 0.06%
3,100
– –
CDXS icon
52
Codexis
CDXS
$158M
– –
-504,279
Closed -$1.18M
DVAX
53
DELISTED
Dynavax Technologies
DVAX
– –
-1,217,900
Closed -$17.4M
ENTA icon
54
Enanta Pharmaceuticals
ENTA
$362M
– –
-250,000
Closed -$9.89M
VRTX icon
55
Vertex Pharmaceuticals
VRTX
$123B
– –
-9,300
Closed -$1.04M
VIRX
56
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-23,187
Closed -$34.8M
ALIM
57
DELISTED
Alimera Sciences
ALIM
– –
-16,248
Closed -$1.32M
AVNR
58
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-5,386,700
Closed -$64.2M
1 2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, RA Capital Management held 58 positions worth $930M, up 10% from $846M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

RA Capital Management withdrew a net $119M in Q4 2014, closing 7 positions and reducing 10 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $64.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 50% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Regulus Therapeutics worth $76.1M.

  • RA Capital Management's largest Q4 2014 buy was Regulus Therapeutics: 39,524 shares worth $76.1M.
  • RA Capital Management added most to TG Therapeutics in Q4 2014, an estimated $16.7M increase.
  • RA Capital Management's biggest Q4 2014 reduction was DYAX CORPORATION, cutting an estimated $35.8M.
  • RA Capital Management fully exited AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, selling an estimated $64.2M.
  • RA Capital Management's ten largest holdings make up 65% of its $930M portfolio in Q4 2014.
  • RA Capital Management opened 12 new positions and closed 7 in Q4 2014.
  • RA Capital Management's portfolio value rose 10% quarter-over-quarter to $930M.

Based on RA Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.